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Abstract (244) 
Introduction: Findings from actigraphic studies that sleep and circadian rhythms are disrupted 
in bipolar disorder (BD) patients have been undermined by methodological heterogeneity and the 
failure to adequately address potential confounders. 
Method: Twenty-six euthymic BD cases and 29 healthy controls (HC), recruited from 
University Paris-Est and matched for age and gender, were compared on subjective (Pittsburgh Sleep 
Questionnaire Inventory; PQSI) and objective (mean scores and variability in actigraphy) measures of 
sleep as recorded by over 21 consecutive days. 
Results: Multivariate generalized linear modelling (GLM) revealed significant differences 
between BD cases and HC for five PSQI items (total score and four subscales), four actigraphy 
variables (mean scores) and five actigraphy variability measures. Backward stepwise linear regression 
(BSLR) indicated that a combination of four variables (mean sleep duration, mean sleep latency, 
variability of the fragmentation index over 21 days, and mean score on PSQI daytime dysfunction sub-
scale) correctly classified 89% of study participants as cases or controls (Chi-square=39.81;df=6; 
p=0.001).   
Limitations: The sample size (although larger than most actigraphy studies) and incomplete 
matching of cases and controls may have influenced our findings. It was not possible to control for 
potential effects of psychotropic medication or differences in employment status between groups. 
Conclusions: When potential confounders of sleep and circadian profiles are adequately taken 
into account (particularly age, gender, daytime sleepiness, mood symptoms, body mass index, and risk 
of sleep apnoea), a selected subset of quantitative (mean scores) and qualitative (variability) features 
differentiated euthymic BD cases from HC. 
 
6 keywords: bipolar disorder; actigraphy; euthymia; remission; sleep; circadian rhythms. 
Actigraphy in Remitted Bipolar Patients 
 3 
INTRODUCTION 
Bipolar disorder (BD) is a severe mental disorder and the worldwide prevalence of the BD 
spectrum is 1–4%. Although researchers agree that BD is multifactorial with inherited, genetic and 
environmental risk factors, the patho-physiological determinants are unknown (Geoffroy et al., 2013). 
Recent studies of circadian genes and phenotypes indicate that sleep/activity dysregulation is a 
plausible model for BD episode recurrence (McClung, 2013). Abnormalities in sleep and circadian 
biomarkers during the euthymic phase have been identified, revealing that this dysregulation is not 
purely an epiphenomenon of acute illness episodes; indeed, increased disruption of the sleep 
homeostasis and circadian system are frequently associated with relapse (Etain et al., 2011; Harvey, 
2008). Consequently, the validation of sleep and circadian biomarkers of BD may help in the 
development both of methods for earlier and more accurate detection of unstable mental states, and of 
novel strategies to prevent relapse (Frey et al., 2013). 
 
Subjective reporting of sleep profiles is useful in clinical practice, although objective measures 
are increasingly utilized for research. Actigraphy (recording the subject’s sleep/wake cycles generally 
with a mobile portable device) is considered to be the most relevant non-invasive technique for the 
measurement of sleep/wake irregularities (Morgenthaler et al., 2007). Actigraphy has been used 
extensively in the field of chronobiology, and has more recently been applied to research in mood 
disorders, and in particular the characterization of sleep homeostasis and circadian rhythm 
abnormalities in BD (Kaplan et al., 2012). We identified nine published actigraphic studies of BD: 
although most suggest that, even in remission, BD cases were more likely than ‘controls’ to display a 
range of sleep abnormalities, there was significant heterogeneity in the methodologies employed 
(Gershon et al., 2012; Harvey et al., 2005; Jones et al., 2005; Kaplan et al., 2012; Millar et al., 2004; 
Mullin et al., 2011; Ritter et al., 2012; Salvatore et al., 2008; St-Amand et al., 2012). The five major 
between-study differences were: 1) the mean age of sample (e.g. ranging from adolescents with early 
onset BD to older adults with chronic, persistent BD); 2) the overall sample size (the total number of 
participants including cases and controls ranging from 27 to 68); 3) the duration of actigraphic 
recording (some studies recorded data for only 3 days with a median of 6 days for the nine studies); 4) 
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different approaches to ‘matching’ cases and controls, with a number of studies failing to match on 
demographic characteristics; and/or 5) failure to control for confounding factors such as body mass 
index (BMI) and/or sleep apnoea syndrome (SAS).   
 
Most of these previous studies examined ‘quantitative’ differences (mean scores of each sleep 
measure for each group), and mainly focused on four basic sleep variables (sleep duration, latency and 
efficiency, and waking after sleep onset). However, it is increasingly argued that differences in terms 
of quality or variability (which can be represented by the standard deviations [SD] in the mean scores 
for a particular measure extracted from actigraphic recordings) may be more sensitive markers for 
distinguishing BD sleep patterns from those of controls (Scott, 2011). Only three studies have 
published data relevant to this approach (Gershon et al., 2012; Millar et al., 2004; Mullin et al., 2011), 
but comparing the findings is difficult. Indeed, the study among adolescents (Mullin et al., 2011), and 
the study involving three days of actigraphic recording (Salvatore et al., 2008) differed from the study 
in older adults over a longer period (28 days) of actigraphic monitoring (Gershon et al., 2012). Also, 
none of these studies controlled for the possible effects of BMI or level of risk for SAS on sleep 
profiles. Thus, published findings for the quality and quantity of sleep in remitted BD may have been 
confounded by other individual characteristics, including those known to affect sleep directly, and by 
heterogeneity in sampling and/or in study design.  
 
To overcome the limitations noted in previous studies, we report an analysis of mean scores of 
subjective and objective measures, and variability in objective measures, using methodological 
approaches designed to avoid potential confounders. Previous studies examined each reported sleep 
variable in independent analyses and none of them adequately addressed potential confounders in their 
statistical analytic strategy. We therefore tried to overcome some of these previous weaknesses in 
design by examining which combination of sleep measures best distinguishes cases from controls. Our 
hypothesis was to identify and/or confirm reliable and robust circadian/sleep markers differentiating 
euthymic BD cases from HC when potential confounders of sleep and circadian differences are taken 
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into account (most notably, age, gender, daytime sleepiness, mood symptoms, BMI and risk of sleep 
apnoea). 
 
MATERIALS AND METHODS 
Sample 
With ethical approval from the Institutional review board, written informed consent was 
obtained from 55 adults (BD=26; HC=29). The included cases were recruited from our university-
affiliated psychiatric clinic (University Paris Est) and the HC were recruited from individuals 
attending the blood donor service at the adjacent general hospital (Henri Mondor Hospital, Creteil).  
The groups (BD and HC) were matched as closely as possible for age and gender: perfect 
matching was not feasible, so we increased the size of the HC group to ensure that we had a control of 
the same age and/or a control of the same gender for each case recruited. Individuals eligible for the 
study were included if, during the preceding three months, they had 1) not experienced any periods of 
severe sleep disruption due to somatic conditions (eg organic insomnia/ hypersomnia, or sleep-wake 
disorders) and/or any life event that may have altered their sleep patterns (e.g. shift work, jet-lag, child 
birth, trauma, or somatic disease known to be associated with sleep disturbances); 2) not been 
hospitalised or received a treatment that may disrupt sleep (e.g. for cases: electro-convulsive therapy); 
3) not been prescribed medication or taken drugs that may disrupt sleep (e.g. sympathomimetic 
stimulants, corticosteroids, thyroid hormone, antiarrhythmics, beta-blockers, clonidine, diuretics, 
theophylline, and medications containing alcohol or caffeine) and not changed either the dose or type 
of psychotropic treatment. 
 
Bipolar cases also had to fulfil the following inclusion criteria: the DSM-IV criteria for BD 
according to the French version of the Diagnostic Interview for Genetic Studies (DIGS) (Nurnberger 
et al., 1988); currently euthymic i.e. they scored <8 on both the Montgomery–Asberg Depression 
Rating Scale (MADRS; Montgomery and Asberg, 1979) and the Young Manic Rating Scale (YMRS; 
Young et al., 1978); and the International Society of Bipolar Disorder task force criteria (Tohen et al., 
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2009) for remission (i.e. they had not experienced a  BD episode in the prior three months). Patients 
experiencing a BD relapse whilst participating in the study were excluded.  
Controls were assessed with the DIGS and the Family Interview for Genetic Studies (Maxwell, 
1992); individuals were excluded if they had any personal history of DSM-IV disorders and no family 
history of schizophrenia, affective disorders and/or suicide attempts.   
 
Assessment Procedures 
Cases and controls were first assessed for affective symptoms using the MADRS and YMRS, 
and their BMI was calculated. Participants then completed the Berlin Questionnaire (a measure of the 
risk of SAS) (Netzer et al., 1999), and the Epworth Sleepiness Scale (a measure daytime sleepiness) 
(Johns, 1991), to allow these potential confounding factors to be taken into account.  
 
Self-Ratings of Sleep Profile  
All participants recorded their subjective sleep quality using the French version of the 19-item 
Pittsburgh Sleep Quality Index (PSQI) (Blais et al., 1997). Here, we report the mean total score over 
21 consecutive days and seven other specific measures of sleep (with higher scores indicating lower 
quality or worse outcome): sleep quality, latency, duration and efficiency, disturbances, use of 
sleeping medication and daytime dysfunction (e.g. sleepiness and enthusiasm).  
 
Actigraphy 
All participants were asked to wear an actigraph (AW-7 CamNtech) on the wrist of their non-
dominant hand for the 21 consecutive days, the days for which they completed the PSQI self-ratings. 
The AW-7 actigraph is an accelerometer that detects the intensity and the amount of movement as a 
function of time. For this study, data were sampled in one-minute epochs and participants were 
instructed to press the event-marker when they went to bed to go to sleep and when they got out of bed 
at the start of the next day. They also completed a sleep diary for these 21 days. Other requirements 
were kept to a minimum to try to minimise intrusion into sleep/activity routines. Recording was made 
during periods when the participants were not on vacation and not involved in unusual activities. 
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Two experienced psychiatrists (PAG and CB) analysed the actigraphic records of cases and 
controls using the sleep detection algorithm provided by Actiwatch software (Actiwatch Activity & 
Sleep Analysis Ltd CamNtech® 7.28) and any incongruences between the sleep diary and actigraphy 
rest periods were clarified prior to statistical analyses (see reference Boudebesse et al., 2012 for 
details).  
We selected the ten clinically interpretable actigraphic measures that have been most frequently 
reported in previous studies (Gershon et al., 2012; Harvey et al., 2005; Jones et al., 2005; Kaplan et 
al., 2012; Millar et al., 2004; Mullin et al., 2011; Ritter et al., 2012; Salvatore et al., 2008; St-Amand 
et al., 2012). There were six measures of basic sleep profile: time in bed, sleep duration, sleep latency, 
wake after sleep onset (WASO), sleep efficiency, fragmentation index (a measure of sleep continuity); 
two measures of activity during sleep: mean activity in active periods of sleep, mean sleep activity; 
and two measures of variability: inter-daily stability and intra-daily variability. To facilitate 
comparison with other studies that used different measures of variability, we also estimated the 
variability of the basic sleep measures over 21 days (using standard deviations (SD) of the mean 
scores) (see references of Millar et al. (2004) and Mullin et al. (2011) for the rationale and details of 
this approach).  
 
Statistical Analysis  
All analyses were performed using SPSS 19.0. We included several covariates in the analysis: 
age and/or gender because matching was incomplete, and also BMI, SAS, daytime sleepiness 
(Epworth) and the presence of residual or low-grade mood symptoms (as measured using the MADRS 
or YMRS) that can all be associated with differences in sleep profile independently of case-control 
group status (i.e. BD or HC). We undertook a power calculation to assess the sample size required to 
detect a between-group Effect Size (ES) of ≥0.35 (classified as a medium ES according to Cohen, 
1977 (Cohen, 1977)) for self-rated and objective measures of sleep whilst controlling for these 
potential confounders. We thereby estimated that the sample size of 55 individuals had >80% power to 
detect differences at a significance level of 0.05 (and an ES≥0.35) in a multivariate analysis.  
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The analysis involved three stages. First, we checked the normality of the distributions of 
variables and undertook log transformation if required (none were needed). Second, we used 
multivariate Generalized Linear Modelling (GLM) for the analysis of sleep variables (self-ratings; 
actigraphy measures). GLM is a flexible statistical model that incorporates normally distributed 
dependent variables and categorical or continuous independent variables (we also report Wilk’s 
Lambda, to indicate the proportion of generalized variance in the dependent variables explained by the 
model and also to give the best estimate of overall power of the analysis to differentiate between 
groups). We used bootstrapping (i.e. resampling) to reduce biases introduced by any ‘outliers’ and to 
obtain the best estimates of summary statistics. Any variables that were significantly different between 
groups (even allowing for interactions between group and other categorical or continuous variables) 
were then entered into a Backward Stepwise Logistic Regression (BSLR) to assess the combination of 
these selected variables that best classified individuals as cases or controls. The proportion of cases 
correctly classified is reported along with the odds ratios (OR) and 95% confidence intervals (95% CI) 
for each variable included in the final optimal model.  
 
 
RESULTS 
Socio-demographic and clinical characteristics  
The sample comprised of 55 individuals (26 BD cases; 29 HC), the mean age was about 54 
years and more than half (30/55) were female (Table 1). Cases fulfilled the criteria for BD subtype I 
(n=16) or BD subtype II (n=10). One patient did not receive medication, and nine patients received 
only one psychotropic medication and 16 received ≥2 medications. The psychotropic treatments used 
were: lithium (n=12), anti-convulsants (n=15), atypical antipsychotics (n=7), typical antipsychotics 
(n=4), benzodiazepines (n=4), antidepressants (n=5). 
There were no statistically significant differences between the groups for age, gender, BMI, 
level of risk of SAS, or daytime sleepiness. Levels of mood symptoms were very low in both groups, 
but the median score on the MADRS was slightly higher for the BD group than controls (0.50 vs. 
0.00); there were no between-group differences on the YMRS.  
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- Insert Table 1 about here – 
 
Mean scores for a number of subjective and objective ratings of sleep differed between cases 
and controls. There were statistically significant differences between the groups for several PSQI and 
actigraphy measures, even when taking into account gender, risk of SAS, age, BMI, and scores on the 
Epworth, MADRS, and YMRS. When considering the multivariate values for the model as a whole, 
there was a significant difference between the patients with BD and HC (Wilks’ lambda, F=90.89; df 
26,16; p=0.0001; statistical power 0.93).  
Several interactions between group and other variables were identified; in particular, five PSQI 
items (Total score and scores for PSQI subscales 1, 4, 5 and 7), four mean actigraphy measures (sleep 
latency, duration, efficacy, and fragmentation index, inter-daily stability) and five actigraphy 
variability measures (variability in sleep duration, sleep efficiency, fragmentation index and time in 
bed) differed between the groups (Table 2). As measured by the PSQI, patients with BD were more 
likely to report poorer sleep quality (p=0.001), poorer sleep efficiency (p=0.001), more frequent sleep 
disturbances (p=0.001), and more daytime dysfunction (p=0.001); consequently they had poorer 
global sleep quality as measured by the PSQI total score (p=0.0001). As determined from mean 
actigraphy scores, patients with BD were more likely to have longer sleep latency (p=0.007), longer 
sleep duration (p=0.02), poorer sleep efficiency (p=0.04), higher fragmentation index (p=0.05) and 
poorer inter-daily stability (p=0.03). For actigraphy variability over 21 days, patients with BD were 
more likely to show more variable time in bed (p=0.005), sleep duration (p=0.04), sleep efficiency 
(p=0.03) and fragmentation index (p=0.03). 
 
- Insert Table 2 about here – 
 
We next used BSLR to determine the optimal combination of variables that best classified 
participants as cases or controls. When the variables identified by the GLM were entered into a BSLR; 
a combination of four variables (mean sleep duration, mean sleep latency, variability in fragmentation 
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index over 21 days, and mean score on PSQI sub-scale 7: daytime dysfunction) correctly classified 
89% of the study participants as cases or controls (Chi-square=39.81; df=6; p=0.001). The OR for 
these variables ranged from 1.03 (sleep duration) to 8.35 (PSQI ‘daytime dysfunction’ sub-scale) 
(Table 3). However, whilst daytime dysfunction is the variable with the highest OR, on its own it 
classified about 75% cases, so the other measures significantly contributed to the improved 
classification obtained by the final model. 
 
- Insert Table 3 about here – 
 
DISCUSSION  
We report a study of sleep abnormalities in remitted bipolar (BD) patients compared with HC 
that also controlled for major potential confounders, and replicate and extend previous findings. In 
particular, objective and subjective assessments of sleep indicate that, compared to controls, BD 
patients show: longer sleep duration, longer sleep latency, poorer sleep efficiency, higher 
fragmentation index (with actigraphy) (Gershon et al., 2012; Harvey et al., 2005; Jones et al., 2005; 
Kaplan et al., 2012; Millar et al., 2004; Mullin et al., 2011; Ritter et al., 2012; Salvatore et al., 2008; 
St-Amand et al., 2012), lower sleep quality, weaker sleep efficiency, more sleep disturbances, and 
more daytime dysfunction (with PSQI) (Rocha et al., 2013). The partial discrepancy between PSQI 
(subjective measure) and actigraphy (objective measure) findings has also been observed previously: 
patients with BD underestimated their sleep latency and duration on questionnaire assessments 
compared to actigraphy examination. This may arise as a consequence of misperceptions in patients 
with BD regarding their sleep quality (Gershon et al., 2012; Harvey et al., 2005; Millar et al., 2004). 
Nevertheless, actigraphy demonstrated a high correlation with polysomnography (PSG) measures in 
patients with BD regarding sleep latency, sleep duration, fragmentation index and sleep efficiency, 
which further validate our findings (Kaplan et al., 2012).  
We report several new findings for issues that have been under–explored: patients with BD 
presented with more variability for time in bed, sleep duration, sleep efficiency and fragmentation 
index. Indeed, sleep duration, sleep efficiency and fragmentation index are altered not only in quantity 
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(mean) but also in variability (SD) in BD patients. This indicates that analyses of actigraphic markers 
should not be restricted to classical sleep markers (latency, duration, efficiency and WASO), but 
should also be extended to the variability of markers. Indeed, Millar et al. were the first to explore the 
variability of markers in different groups and showed that the means of none of the four actigraphic 
measure differed between cases and controls, but variability of two of the four measure did (sleep 
duration and night waking time) with an effect size around 0.35 (Millar et al., 2004). Similarly, 
Gershon et al. confirmed more variability of both time in bed and sleep duration for BD patients than 
controls (although the latter did not survive their Bonferroni’s correction) (Gershon et al., 2012). 
Millar et al. also found more variability of night wake time among remitted cases (Millar et al., 2004). 
Both Gershon et al. (2012) and our study (0.40±0.3 vs. 0.36±0.3) replicate this finding. Further, we 
observed significant variability of sleep efficiency and fragmentation index, which confirmed the 
greater variability of sleep patterns and circadian rhythms in patients with remitted BD than controls. 
Mullin et al., despite also assessing the variability of actigraphic measures, did not find any significant 
differences (Mullin et al., 2011); however, that study involved recordings for only four nights, which 
may have been too short to detect variability. Studies involving sufficient duration of recording would 
be useful to explore further the variability of actigraphic measures in BD patients, and to examine 
trait-markers of BD. 
 
The results of our regression analysis deserve comment. The fact that 89.3% of BD and 88.5% 
of HC could be correctly classified indicates that a combination of different methods of assessment 
(i.e PSQI, mean and SD actigraphy measures) may serve as a useful marker of BD. Daytime 
dysfunction, sleep duration, sleep latency and fragmentation index variability appeared, when 
combined, to identify clear circadian biomarkers of remitted BD. Indeed, it may be possible to define a 
biosignature of BD using these four features. We partially replicate the findings of Millar et al. whose 
best multivariate model involved a combination of one actigraphic (variability of sleep duration) and 
two subjective sleep variables (average sleep duration, and average onset latency) (Millar et al., 2004). 
These two studies indicate that individuals are best classified by a combination of subjective and 
objective measures (quantity and variability). The other comment is that it is noteworthy that- 
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although daytime dysfunction- was a subscale score of the PSQI, it is debatable whether this is a 
specific measure of sleep pattern/dysfunction. Indeed in BD cases it may be a measure of overall 
effects of illness or possible effects of medication, not only of daytime consequences of disturbed 
sleep.  
 
Our study has some limitations. Controlling for psychotropic medications is always difficult in 
bipolar disorder research. In this study, the size of the case sub-group did not allow us to include 
treatment data as a covariate in any ‘within group’ sub-analyses. However, the type and dose of 
psychotropic medications have been found to be unrelated to actigraphic measures in patients with 
remitted BD (Salvatore et al., 2008). Moreover, we believe that on balance, it can be hypothesized that 
medication would be as likely or more likely to improve the patients’ quality of sleep as to have a 
detrimental effect. We also attempted to control for daytime sedation by using scores on the Epworth 
scale as a covariate in the preliminary between group comparisons. As such, the observed differences 
between cases and controls may have been attenuated rather than exaggerated by such treatments. 
Indeed, antipsychotics, valproate and lithium have been shown to regulate sleep and circadian rhythms 
in patients with bipolar disorder (Geddes and Miklowitz, 2013). Therefore, we believe that it is 
unlikely that psychotropic drugs had a major influence. Our sample size is small; however, it is of 
reasonable size for an actigraphic study and larger than the median for the previous studies cited 
(median = 40) (Gershon et al., 2012; Harvey et al., 2005; Jones et al., 2005; Kaplan et al., 2012; Millar 
et al., 2004; Mullin et al., 2011; Ritter et al., 2012; Salvatore et al., 2008; St-Amand et al., 2012). We 
studied several markers of subjective and objective sleep. Although GLM is an appropriate method for 
assessing multiple, potentially inter-dependent measures, and the power calculation (and estimated 
effect sizes) suggest we have reduced the risk of type II error, it is clear that it would be beneficial to 
use a larger sample for further studies. Nevertheless, our study allowed controlling for confounding 
factors that were insufficiently taken into account in previous studies; our greater attention to potential 
confounding factors was an important methodological strength relative to most previous studies.   
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We were thus able to confirm that patients with BD in remission experienced substantial sleep 
disturbances that can be measured both objectively and subjectively. This provides further evidence of 
the involvement of sleep and circadian rhythm abnormalities in the pathophysiology of BD, as 
proposed by, e.g., Harvey et al. (Harvey, 2008). Indeed, genetic variants of candidate genes (mainly 
circadian genes) may predispose individuals to be relatively less able to adapt their circadian rhythms 
appropriately to their environment, and therefore to greater vulnerability to sleep disturbances. Since 
circadian and neurotransmission systems are highly connected, circadian and/or sleep-related 
abnormalities may affect the functioning of the dopamine and serotonin circuitry, which in turn may 
affect mood regulation. These chronic sleep and circadian rhythm disturbances (observable in acute 
episodes and in remission) may thereby contribute to the more general issues persistently encountered 
bipolar patients such as poor quality of cognitive functioning, residual emotional hyper-reactivity or 
vulnerability to metabolic disturbances (Boland et al., 2012; Boudebesse and Henry, 2012; McClung, 
2013; Soreca et al., 2012).  
 
The findings we report have several important clinical implications. Sleep and circadian rhythm 
disturbances in remitted BD might be treatable by manipulating the circadian system using 
chronobiological medication (e.g. melatonin or melatonin analogues) or sleep focused psychological 
interventions (Kaplan and Harvey, 2013; Livianos et al., 2012; Pacchierotti et al., 2001; St-Amand et 
al., 2012). Attention to rhythm abnormalities is of particular interest because biological rhythm 
dysfunctions have been found to be associated to a wide range of sources of poor functioning and are 
the earliest markers of impending mood relapses (Giglio et al., 2010). Thus, better identification of 
these abnormalities in clinical practice might facilitate the prevention of the evolution of prodromes of 
mood relapses, and also help improve functioning in inter-episodic BD. It may allow a more complete 
approach including combinations of treatments acting on several dimensions including sleep or 
circadian disturbances (Geoffroy et al., 2012). These findings more generally indicate a new area for 
research both into possible therapeutic targets and to improve our understanding of the circadian 
pathophysiology of BD. 
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CONCLUSION  
This 21-day case-control study demonstrates the presence of subjective and objective 
disturbances of sleep and activity markers in patients with BD during remission. Disturbances 
identified by actigraphy are both quantitative (mean scores) and qualitative (variability). We further 
confirm the greater variability in sleep markers in remitted patients with BD. These findings indicate 
that future studies should examine both the mean scores and the variability over extended periods of 
time. In addition, we show that a combination of subjective and objective measures (quantity and 
variability) may be a better circadian biosignature of BD than any single measure on its own.  
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Table 1: Baseline characteristics of bipolar disorder (BD) cases and healthy controls 
(HC) 
 
 
 
BD (n=26) 
Mean (±SD) 
HC (n=29) 
Mean (±SD) 
p 
Age (years)  53.50 (±11.49) 54.10 (±9.11)  0.78 
Montgomery Asberg 
Depression Rating Scale 
Median score 
1.85 (±2.80) 
 
0.50  
0.48 (±1.35) 
 
0.00  
0.02 
Young Mania Rating 
Scale 
Median score 
0.65 (±1.38) 
0.00 
0.14 (±0.44) 
0.00 
0.16 
Body Mass Index 26.74 (±5.72) 26.64 (±4.17)  0.68 
Daytime Sleepiness**  8.85 (±3.90) 6.86 (±3.72) 0.12 
 n (%) n (%)  
Sleep Apnoea 
Syndrome*: High Risk 
Category 
Low Risk Category 
 
6 (23%) 
20 (77%) 
 
2 (7%) 
27 (93%) 
0.09 
Gender Distribution: 
Female 
Male 
 
17 (65%) 
9 (35%) 
 
13 (45%) 
16 (55%) 
0.13 
*Risk of Sleep Apnoea Syndrome assessed using the Berlin Questionnaire  
**Daytime sleepiness assessed using the Epworth Sleepiness Scale  
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Table 2: Differences between sleep measures for cases (BD) and controls (HC)  
 
BD  (n=26) 
Mean (±SD) 
HC  (n=29) 
Mean (±SD) 
Multivariate Generalized Linear 
Model*  
F p Observed 
Power 
PSQI measures 
Total score 
7.38 
(±3.49) 
4.11 
(±2.13) 
4.45 0.0001 0.99 
Sub-scale 1  
Subjective sleep quality 
1.19 
(±0.69) 
0.71 
(±0.66) 
3.64 0.001 0.99 
Sub-scale 2  
Sleep latency 
1.19 
(±0.80) 
0.82 
(±0.91) 
0.70 0.74 0.33 
Sub-scale 3  
Sleep duration 
0.62 
(±0.94) 
0.50 
(±0.75) 
1.53 0.15 0.70 
Sub-scale 4  
Habitual sleep efficiency 
0.88 
(±0.95) 
0.43 
(±0.69) 
3.86 0.001 0.99 
Sub-scale 5  
Sleep disturbances 
1.58 
(±0.58) 
1.18 
(±0.48) 
3.67 0.001 0.99 
Sub-scale 6  
Use of night sedation  
0.69 
(±1.09) 
0.14 
(±0.59) 
1.08 0.18 0.68 
Sub-scale 7  
Daytime dysfunction 
1.23 
(±0.99) 
0.32 
(±0.48) 
3.53 0.001 0.98 
Mean actigraphy scores 
Time in bed (mins) 
 
511.81 
(±50.28) 
482.31 
(±49.36) 
1.79 0.08 0.79 
Sleep duration (mins) 
 
475.42 
(±64.5) 
455.83 
(±53.98) 
2.38 0.019 0.91 
Sleep latency (mins) 
 
25.23 
(±33.65) 
11.59 
(±7.98) 
2.81 0.007 0.95 
Wake after sleep onset 
(mins) 
57.88 
(±23.17) 
52.62 
(±27.33) 
0.57 0.85 0.27 
Sleep efficiency (%) 81.54 
(±9.87) 
84.90 
(±6.32) 
2.13 0.036 0.86 
Fragmentation index 32.04 
(±10.51) 
28.69 
(±10.88) 
2.01 0.05 0.84 
Mean activity in active 
sleep periods** 
115.54 
(±37.67) 
91.10 
(±24.39) 
1.21 0.31 0.58 
Mean overall sleep activity 19.35 
(±13.10) 
12.69 
(±7.07) 
1.69 0.11 0.76 
Inter-daily stability 0.503 
(±0.14) 
0.512 
(±0.12) 
2.17 0.033 0.87 
Intra-daily variability 0.82 
(±0.17) 
0.80 
(±0.18) 
0.90 0.56 0.43 
Actigraphy measure variability over 21 days 
Time in bed (mins) 
 
1.44 
(±0.7) 
1.33 
(±0.5) 
2.97 0.005 0.96 
Sleep duration (mins) 1.3 
(±0.6) 
1.13 
(±0.4) 
2.08 0.04 0.86 
Sleep latency (mins) 
 
0.67 
(±1.2) 
0.43 
(±0.7) 
1.40 0.21 0.66 
Wake after sleep onset 
(mins) 
0.49 
(±0.3) 
0.36 
(±0.3) 
1.80 0.08 0.79 
Sleep efficiency (%) 8.77 
(±7.5) 
6.13 
(±3.8) 
2.26 0.026 0.89 
Fragmentation index 12.52 
(±7.3) 
9.28 
(±2.7) 
2.16 0.033 0.96 
*Model controlled for age, gender, daytime sleepiness (Epworth), current mood symptoms (MADRS and YMRS), BMI and risk of sleep 
apnoea (Berlin);  
**Intensity of movement during periods of sleep when activity occurs   
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Table 3: Backward Stepwise Logistic Regression (BSLR) showing (a) the best 
combination of variables for correctly classifying study participants as cases or controls 
and (b) the overall classification rate by group  
 
3a) Variables included in the final BSLR model 
 
Variable 
p Odds Ratio 
95% C.I. 
Lower Upper 
 Sleep Duration 
 
0.015 1.03 1.01 1.05 
Sleep Latency 
 
0.012 1.24 1.05 1.47 
Fragmentation Index: Mean Variability 
 
0.01 1.63 1.12 2.31 
Daytime Dysfunction 
 (PSQI Subscale-7) 
0.005 8.35 2.50 18.11 
 
 
 
 
3b) Classification table and summary statistics 
 
 
 
 
 
 
 
 
 
*1 control participant was excluded from the analysis due to inadequate data 
 
 
 
 
Observed 
Predicted 
Controls Cases 
% Correctly 
Classified 
  Controls* 25 3 89.3% 
Cases 3 23 88.5% 
 
  
 
% of all participants correctly classified 89% 
Chi-square 39.81 (df 6) p=0.001 
